Finance

Lists
Why is NVS up 2,86%?
Dive Deeper
NVS:NYSE
ნოვარტისი
146,49 US$
+2,86%
(+4,08) 1D
14 ოქტ, 13:00:25 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Open
144,35 US$
High
146,55 US$
Low
144,17 US$
Mkt. cap
300,02 მლრ.
Avg. vol.
2,40 მლნ.
Volume
805,16 ათ.
Dividend
3,24%
Quarterly dividend
1,19 US$
Ex-dividend date
10 მარ. 2026
P/E ratio
22,13
52-wk high
170,46 US$
52-wk low
121,57 US$
EPS
6,62 US$
Beta
0,39
Shares outstanding
2,03 მლრდ.
No. of employees
75 ათ.
Open
144,35 US$
High
146,55 US$
Low
144,17 US$
Mkt. cap
300,02 მლრ.
Avg. vol.
2,40 მლნ.
Volume
805,16 ათ.
Dividend
3,24%
Quarterly dividend
1,19 US$
Ex-dividend date
10 მარ. 2026
P/E ratio
22,13
52-wk high
170,46 US$
52-wk low
121,57 US$
EPS
6,62 US$
Beta
0,39
Shares outstanding
2,03 მლრდ.
No. of employees
75 ათ.
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
4 საათის წინ
MindWalk adds three executives from Pfizer, Novartis, Arbor By Investing.com
ad-hoc-news.de
ad-hoc-news.de
·
6 საათის წინ
Erste Group raised its Novartis stock forecast to USD 9.24
News Corp
News Corp
·
22 საათის წინ
Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
ad-hoc-news.de
ad-hoc-news.de
·
1 დღის წინ
Morgan Stanley cuts target for Novartis stock to USD 156.00
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About ნოვარტისი
CEOვასანტ ნარასიმჰანი
Employees75,3 ათ.
Founded7 მარ. 1996
Headquartersბაზელი, ბაზელ-შტადტის კანტონი, შვეიცარია
SectorPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to NVS in the past 3 months
Buy
Buy
3
Hold
3
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current 146,49 US$
180,25 US$ (+23,05%)
Average
158,32 US$ (+8,08%)
Lowest
136,00 US$ (-7,16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sachin Jain
Bank of America Securities
Buy
Maintained
150,00 CHF
+2,4%
10/12/2026
Thibault Boutherin
Morgan Stanley
Buy
Maintained
156,00 US$
+6,5%
10/06/2026
Rajesh Kumar
HSBC
Hold
Upgraded
136,00 US$
-7,2%
09/10/2026
Steve Scala
TD Cowen
Hold
Maintained
180,00 US$
+22,9%
09/08/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
147,00 US$
+0,3%
07/27/2026
Jasper Hellweg
Argus Research
Buy
Maintained
170,00 US$
+16%
07/24/2026
Unknown Analyst
Goldman Sachs
Sell
Maintained
139,00 US$
-5,1%
07/22/2026
Justin Smith
Bernstein
Hold
Initiated
-
-
03/19/2026
David Toung
Argus Research
Buy
Upgraded
180,00 US$
+22,9%
03/11/2026
Next call 13 დღეში
სამ, 27 ოქტ, 18:40
Fiscal period
Q3 2026
- / 2,24 US$
Revenue / Est. (USD)
- / 14,67 მლრდ.
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
14,36 მლრდ.
13,86 მლრდ.
13,52 მლრდ.
14,95 მლრდ.
Cost of goods sold
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
3,68 მლრდ.
Cost of revenue
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
3,68 მლრდ.
Research and development expenses
2,86 მლრდ.
2,84 მლრდ.
2,78 მლრდ.
2,74 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 მლრდ.
3,44 მლრდ.
3,14 მლრდ.
3,23 მლრდ.
Operating expense
6,24 მლრდ.
6,46 მლრდ.
5,96 მლრდ.
6,10 მლრდ.
Total operating expenses
9,77 მლრდ.
10,00 მლრდ.
9,40 მლრდ.
9,78 მლრდ.
Operating income
4,58 მლრდ.
3,86 მლრდ.
4,12 მლრდ.
5,18 მლრდ.
Other non operating income
-7,00 მლნ.
-130,00 მლნ.
4,00 მლნ.
19,00 მლნ.
EBT including unusual items
4,20 მლრდ.
3,22 მლრდ.
3,84 მლრდ.
4,27 მლრდ.
EBT excluding unusual items
4,29 მლრდ.
3,49 მლრდ.
3,78 მლრდ.
4,73 მლრდ.
Income tax expense
266,00 მლნ.
814,00 მლნ.
683,00 მლნ.
1,01 მლრდ.
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 მლნ.
190,00 მლნ.
42,00 მლნ.
127,00 მლნ.
Net income
3,93 მლრდ.
2,41 მლრდ.
3,16 მლრდ.
3,26 მლრდ.
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 მლნ.
-
-
Interest expense
-281,00 მლნ.
-304,00 მლნ.
-343,00 მლნ.
-462,00 მლნ.
Net interest expenses
-281,00 მლნ.
69,00 მლნ.
-343,00 მლნ.
-462,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 მლრდ.
4,96 მლრდ.
5,24 მლრდ.
6,30 მლრდ.
Gain or loss from assets sale
81,00 მლნ.
80,00 მლნ.
-159,00 მლნ.
-247,00 მლნ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები